EN


宏观视角(含综合性分析报告、投融资、管线等涉及多类别领域的报告)

请复制链接至电脑/手机浏览器查阅

序号

发布单位

标题

链接

日期

备注

1

WHO

Arenaviridae Research & Development Roadmap

https://cdn.who.int/media/docs/default-source/consultation-rdb/arenaviridae-r-d-roadmap.pdf?sfvrsn=f898cc59_3&download=true

2026/3/12


2

国泰海通证券

2026年医药产业政策展望:“两会”绘蓝图,“十五五”新征途

https://www.fxbaogao.com/view?id=5298223&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/3/12

需注册账号,每日限制次数阅读、收费下载

3

国信证券

创新药盘点系列报告(25):IgA肾病药物已进入商业化兑现期

https://pdf.dfcfw.com/pdf/H3_AP202603121820524391_1.pdf?1773341960000.pdf

2026/3/12


4

东吴证券

创新药进入收获期,仿制药CRO/CDMO困境反转

https://consult.pharnexcloud.com/report/detail/114791.html

2026/3/12

需注册账号,每日限制次数下载

5

药智

2025年度中国医药领域专利发展分析报告

https://db.yaozh.com/reportcenter/info/id/550.html

2026/3/9

需提供信息查阅、下载

6

国泰海通证券

AI制药持续进展,跨国药企布局加速

https://www.fxbaogao.com/view?id=5291802&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/3/9

需注册账号,每日限制次数阅读、收费下载

7

万联证券

医药生物行业深度报告:投融资与出海双轮驱动,CXO迎来景气度修复与全球化新周期

https://pdf.dfcfw.com/pdf/H3_AP202603091820422805_1.pdf?1773095033000.pdf

2026/3/9


8

信达证券

新兴生物技术专题报告:小核酸药物方兴未艾,海外创新与国内崛起共振

https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf

2026/3/9


9

信达证券

临床CRO行业深度跟踪:供需关系改善,有望驱动订单量价齐升

https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf

2026/3/9


10

国金证券

医药行业研究:靶蛋白降解:下一代颠覆性治疗范式迎来商业化元年

https://pdf.dfcfw.com/pdf/H3_AP202603101820434538_1.pdf?1773128891000.pdf

2026/3/6


11

国泰海通证券

延续心血管优势,核酸药物递送加速破局

https://www.fxbaogao.com/view?id=5286735&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/3/5

需注册账号,每日限制次数阅读、收费下载

12

艾昆纬

The Human Edge of AI: Building Trust, Safety and Value in Regulated Healthcare Systems

https://www.iqvia.com/library/white-papers/building-trust-safety-and-value-in-regulated-healthcare-systems

2026/3/5


13

头豹研究院

2026年过敏性鼻炎药物品牌推荐双效合一,快速通鼻

https://pdf.dfcfw.com/pdf/H3_AP202603051820308917_1.pdf?1772741320000.pdf

2026/3/5


14

埃森哲

从实验室到生产线 重新定义生物制药

https://pdf.dfcfw.com/pdf/H3_AP202602281820143602_1.pdf?1772313511000.pdf

2026/2/28


15

浙商证券

临床前CRO系列专题报告(一):实验猴供需缺口大,持续看好临床前CRO深度研究

https://www.fxbaogao.com/view?id=5278312&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/27

需注册账号,每日限制次数阅读、收费下载

16

国信证券

海外制药企业2025Q4&全年业绩回顾:2026会是下一个BD大年吗?

https://pdf.dfcfw.com/pdf/H3_AP202602271820085454_1.pdf?1772184151000.pdf

2026/2/26


17

国泰海通证券

FXI/FXIa抑制剂行业研究报告:从靶点到管线,FXI引领抗凝产业新变革

https://www.fxbaogao.com/view?id=5273273&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/25

需注册账号,每日限制次数阅读、收费下载

18

高盛

Byte-ology: Quantifying AI’s value creation in drug development

https://www.fxbaogao.com/view?id=5272705&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/20

需注册账号,每日限制次数阅读、收费下载

19

上海现代服务业联合会&荣续智库

医养康行业ESG白皮书

https://www.fxbaogao.com/view?id=5274571&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/20

需注册账号,每日限制次数阅读、收费下载

20

Morgan Stanley

北美生物制药行业观点更新

https://www.fxbaogao.com/view?id=5272710&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/20

需注册账号,每日限制次数阅读、收费下载

21

新世纪评级

医药制造与流通行业2025年信用回顾与2026年展望

https://www.fxbaogao.com/view?id=5274583&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/15

需注册账号,每日限制次数阅读、收费下载

22

McKinsey

Life sciences: Dealmaking gains momentum as strategic pressures intensify

https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify

2026/2/13

需提供信息下载

23

DRAKE STAR PARTNERS

远程医疗:2025年回顾与2026展望

https://pdf.dfcfw.com/pdf/H3_AP202602101819861840_1.pdf?1770801724000.pdf

2026/2/11


24

中诚信国际

中国医药制造行业展望

https://pdf.dfcfw.com/pdf/H3_AP202602111819874195_1.pdf?1770818751000.pdf

2026/2/11


25

德勤

2026年生命科学行业展望:生命科学行业高管认为企业财务前景比较乐观,但需在复杂国际局势中增强韧性

https://pdf.dfcfw.com/pdf/H3_AP202602091819838338_1.pdf?1770663694000.pdf

2026/2/9


26

艾昆纬

优化早期临床试验以实现快速、基

于证据的决策

https://pdf.dfcfw.com/pdf/H3_AP202602111819871322_1.pdf?1770809000000.pdf

2026/2/9


27

ITIF

Tracking R&D Leadership: US Advantage Narrowing as China Gains Groun

https://www.fxbaogao.com/view?id=5263576&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/9

需注册账号,每日限制次数阅读、收费下载

28

艾昆纬

中东非洲药品商业洞察(第三十八版)

https://pdf.dfcfw.com/pdf/H3_AP202602281820143624_1.pdf?1772313733000.pdf

2026/2/9


29

美国癌症协会

医药:癌症事实与数据2026

https://pdf.dfcfw.com/pdf/H3_AP202602071819822659_1.pdf?1770565915000.pdf

2026/2/8


30

药智

2025年度全球医药交易分析报告

https://db.yaozh.com/reportcenter/info/id/537.html

2026/2/6

需提供信息查阅、下载

31

广州中康资讯

《中国创新药蓝皮书(2025)》报告第一章

https://pdf.dfcfw.com/pdf/H3_AP202602061819815133_1.pdf?1770416780000.pdf

2026/2/6


32

海通国际

美国医药调研反馈:肿瘤、代谢、自免、中枢神经系统赛道推荐更新

https://www.fxbaogao.com/view?id=5259033&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/6

需注册账号,每日限制次数阅读、收费下载

33

西南证券

创新药专题:中国声音响彻2026JPM大会

https://pdf.dfcfw.com/pdf/H3_AP202602061819806370_1.pdf?1770389935000.pdf

2026/2/6


34

国泰海通证券

美国医药调研及JPM大会后反馈

https://www.fxbaogao.com/view?id=5257867&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/2/5

需注册账号,每日限制次数阅读、收费下载

35

头豹研究院

2025年中国生物创新药市场跟踪报告:司美格鲁肽2025年第一季度市场回顾

https://pdf.dfcfw.com/pdf/H3_AP202602041819774404_1.pdf?1770239567000.pdf

2026/2/4


36

智药局

2025 AI制药行业研究报告

https://mp.weixin.qq.com/s/vqYQG9S2OJ-PtbaoRAa58A

2026/2/4

需提供信息获取

37

药智

2025年度全球新药研发进展

https://db.yaozh.com/reportcenter/info/id/535.html

2026/2/2

需提供信息查阅、下载

38

信达证券

政策引导&技术支持”助力AI医疗崛起,蚂蚁阿福或成C端应用范例

https://pdf.dfcfw.com/pdf/H3_AP202601301818576386_1.pdf?1769780721000.pdf

2026/1/28


39

摩熵咨询

2025全球罕见病行业发展报告:政策演进、市场趋势与领先企业布局

https://pdf.dfcfw.com/pdf/H3_AP202601281818514005_1.pdf?1769635872000.pdf

2026/1/26


40

中邮证券

医药生物行业:国家统计局公布各项经济与人口数据,65岁及以上人口占比进一步提升

https://pdf.dfcfw.com/pdf/H3_AP202601261818423652_1.pdf?1769439930000.pdf

2026/1/26


41

国信证券

医药生物行业2026年投资策略:关注创新出海,重视新技术方向

https://pdf.dfcfw.com/pdf/H3_AP202601271818448366_1.pdf?1769501702000.pdf

2026/1/26


42

开源证券

北交所策略专题报告:药械出海获顶层设计加速,掘金北交所、新三板专精特新稀缺资产

https://www.fxbaogao.com/view?id=5239334&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/25

需注册账号,每日限制次数阅读、收费下载

43

PitchBook

The Chinese Biopharma Landscape: Where New Assets Are Born(新兴技术研究:中国生物医药格局:新资产诞生之地)

https://pdf.dfcfw.com/pdf/H3_AP202602071819822655_1.pdf?1770566304000.pdf

2026/1/23


44

FDA

Advancing Health Through Innovation: New Drug Therapy Approvals 2025

https://www.fda.gov/media/190705/download?attachment

2026/1/23


45

广州洞犀企业咨询

口腔产业投融资观察(2025

https://pdf.dfcfw.com/pdf/H3_AP202601231818320268_1.pdf?1769185770000.pdf

2026/1/23


46

信达证券

CXO行业跟踪报告:高景气度有望持续,JPM大会更新要点解读

https://pdf.dfcfw.com/pdf/H3_AP202601231818303539_1.pdf?1769156127000.pdf

2026/1/22


47

摩熵咨询

IgA肾病药物研发全景及已上市药物市场竞争格局报告

https://consult.pharnexcloud.com/report/detail/114355.html

2026/1/22

需注册账号,每日限制次数下载

48

中邮证券

AI制药:从降本增效到分子创新,数据生产构筑长期壁垒

https://pdf.dfcfw.com/pdf/H3_AP202601221818269607_1.pdf?1769094912000.pdf

2026/1/22


49

西南证券

药品专题报告:2025年药品BD出海总结

https://pdf.dfcfw.com/pdf/H3_AP202601211818190934_1.pdf?1768988442000.pdf

2026/1/21


50

WHO

WHO's response to the global mpox outbreak

https://cdn.who.int/media/docs/default-source/documents/health-topics/monkeypox/who-s-response-to-the-global-mpox-outbreak-donor-report-august-2025-september-2025.pdf?sfvrsn=e0c3fb48_3&download=true

2026/1/21


51

艾昆纬

An Agentic AI-Powered Consumer Health Revolution: Scenarios on How Foundation Models and AI Agents Could Transform Discovery, Trust, and Commerce

https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/an-agentic-ai-powered-consumer-health-revolution.pdf

2026/1/20


52

Vi Labs

State of AI in Wellness 2026

https://www.fxbaogao.com/view?id=5232069&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/20

需注册账号,每日限制次数阅读、收费下载

53

UBS AG

Q-Series Redux: Global Medtech Dragons through the gate; entering a new era ofcompetition

https://www.fxbaogao.com/view?id=5227146&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/15

需注册账号,每日限制次数阅读、收费下载

54

西南证券

CXO跟踪报告:关注新分子的成长性与国内景气度修复的传导

https://pdf.dfcfw.com/pdf/H3_AP202601151817082480_1.pdf?1768510551000.pdf

2026/1/15


55

硕远咨询

2025年中国母婴医疗服务行业市场研究报告

https://www.fxbaogao.com/view?id=5223219&requestId=2601194187293593&query=%7B%22keywords%22%3A%222025年中国母婴医疗服务行业市场研究报告%22%2C%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/14

需注册账号,每日限制次数阅读、收费下载

56

药智

2025年度中国上市药品分析报告

https://db.yaozh.com/reportcenter/info/id/528.html

2026/1/14

需提供信息查阅、下载

57

McKinsey

Capturing value from customer-centric medtech services

https://www.mckinsey.com/industries/life-sciences/our-insights/capturing-value-from-customer-centric-medtech-services

2026/1/14

需提供信息下载

58

艾昆纬

Clinical Trials in Tuberculosis Across Asia Pacific: Navigating Challenges and Exploring Solutions

https://www.fxbaogao.com/view?id=5241337&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/13

需注册账号,每日限制次数阅读、收费下载

59

药智

2025年度CDE药审分析报告

https://db.yaozh.com/reportcenter/info/id/526.html

2026/1/13

需提供信息查阅、下载

60

Capgemini

Smart bet,only option,or both? Biopharma R&Dturns to Al.

https://www.capgemini.com/wp-content/uploads/2026/01/140126CRI_Gen-AI-in-Lifesciences-_Final-interactive-1.pdf

2026/1/13


61

头豹研究院

2025年中国带状疱疹疫苗行业洞察报告:免疫需求扩容+政策红利加持背景下,百克生物率先获批,国产疫苗如何承接市场?

https://pdf.dfcfw.com/pdf/H3_AP202602241819998923_1.pdf?1771961794000.pdf

2026/1/13


62

艾昆纬

A New, AI-Augmented Horizon for Safety and Pharmacovigilance:Expert Predictions for 2026

https://www.fxbaogao.com/view?id=5224741&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/12

需注册账号,每日限制次数阅读、收费下载

63

中泰证券

脑机接口、小核酸行情如火如荼,积极把握医药春躁行情

https://www.fxbaogao.com/view?id=5221193&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/11

需注册账号,每日限制次数阅读、收费下载

64

艾昆纬

肺动脉高压临床试验教育者的演进与影响

https://pdf.dfcfw.com/pdf/H3_AP202601071816825683_1.pdf

2026/1/8


65

万联证券

2025FDA新药全景:创新疗法与市场变革——医药生物行业跟踪报告

https://pdf.dfcfw.com/pdf/H3_AP202601081816835695_1.pdf?1767860577000.pdf

2026/1/8


66

艾昆纬

Trustworthy AI/ML for Patient Analytics and Research

https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/trustworthy-aiml-for-patient-analytics-and-research---final.pdf

2026/1/7


67

联合资信评估

医药制造行业2026年度信用风险展望

https://pdf.dfcfw.com/pdf/H3_AP202601071816798126_1.pdf?1767808943000.pdf

2026/1/7


68

McKinsey

The emerging epicenter: Asia’s role in biopharma’s future

https://www.mckinsey.com/industries/life-sciences/our-insights/the-emerging-epicenter-asias-role-in-biopharmas-future#/

2026/1/7

需提供信息下载

69

太平洋证券

医药行业2026年度策略报告:创新药产业链景气度持续提升

https://pdf.dfcfw.com/pdf/H3_AP202601061815853167_1.pdf?1767687989000.pdf

2026/1/6


70

爱建证券

2026年医药行业投资策略:创新出海新征程,寻找需求新增量

https://pdf.dfcfw.com/pdf/H3_AP202601061815857250_1.pdf?1767688824000.pdf

2026/1/6


71

招商证券

全球医药、医疗行业:2026年关注慢病迭代经营质量和现金流

https://www.fxbaogao.com/view?id=5215406&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=

2026/1/5

需注册账号,每日限制次数阅读、收费下载

72

北京蛋黄科技

2025创新药及供应链年度创新白皮书:分化加速,行业回归平台与产品价值

https://pdf.dfcfw.com/pdf/H3_AP202601041814560749_1.pdf?1767525627000.pdf

2026/1/4


73

太平洋证券

2026年度医药行业投资策略:聚焦创新,共赴新程

https://pdf.dfcfw.com/pdf/H3_AP202601041814519850_1.pdf?1767519175000.pdf

2026/1/4


74

艾昆纬

中风领域的发展:关键管道和临床试验见解

https://pdf.dfcfw.com/pdf/H3_AP202601041814560829_1.pdf?1767526172000.pdf

2026/1/4




联系方式
地址:南京市江宁区龙眠大道639号
邮编:211198
邮箱:zkb@cpu.edu.cn
版权所有© 2024中国药科大学生物医药战略研究院